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INTRODUCTION
Juvenile dermatomyositis (JDM) is a non-suppurative 
inflammatory disorder of the skeletal muscles and skin. Other 
organs and systems, such as the lungs, gastrointestinal tract, 
subcutaneous tissue, eyes, and heart, can be involved.1-6 
Pulmonary complications are associated with high 
morbimortality rates and, usually, develop in the acute phase 
of the disease in up to 10% of the patients.1,3,4
Pulmonary involvement includes interstitial disease 
(pneumonitis or fibrosis), aspiration pneumonia, restrictive lung 
disease, ventilatory failure secondary to muscular weakness, 
infectious pneumonia, and drug-induced pneumonitis.2,5
Interstitial lung disease (ILD) seems to be the most 
common complication in adult patients with dermatomyositis 
(DM), affecting approximately 50% of the cases.2,5-7 The 
main symptoms include coughing and dyspnea, but it can be 
asymptomatic in 5 to 50% of the cases of DM in the first years 
of the disease.2,6,7
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ABSTRACT
Juvenile dermatomyositis (JDM) is an inflammatory, non-pustular disorder of skeletal muscles and skin. Other organs, 
such as the lungs, can be involved. Pulmonary complications are associated with high morbimortality rates and can 
develop in the acute phase of the disease. Due to its rarity, diagnosis difficulty and severity pulmonary involvement, we 
report the case of a 3-year-old girl with JDM and pulmonary involvement and evolution to death. 
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Additional tests for the diagnosis of lung involvement 
include chest X-ray, multislice chest computerized tomography 
(MSCT), and pulmonary function tests (PFTs).1,2
There are few reports of patients with JDM and lung 
involvement. Most of them include severe cases, or cases 
refractory to treatment, which evolve to death.1,3,4,6
Due to its rarity, diagnosis difficulty and severity pulmonary 
involvement, we report the case of a 3-year-old girl with JDM 
and lung involvement and evolution to death.
CASE REPORT
Girl, 3 years and 9 months old, white, with a history of weight 
loss, progressive weakness, arthritis in the knees, skin rash with 
photosensitivity, and cutaneous ulcers in the tip of her fingers 
and ears for nine months. She had no fever and was hospitalized 
for pneumonia one month before this hospital admission.
On physical examination, her condition was regular, 
with decreased weight, mucous membranes were pale, she 
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Figure 1. Chest X-ray with diffuse interstitial infiltrate and increased 
heart area.
had bilateral basilar crackles on lung examination, and 
hepatosplenomegaly; heart examination was normal. She also 
presented diffuse alopecia, vasculitis in the sole of her feet and 
nail folds, Gottron’s sign, ulcers in the tip of her fingers and 
ears, Raynaud’s phenomenon in the extremities, and bilateral 
arthritis of the knees, besides muscle weakness.
Laboratory tests revealed hemoglobin 10.7 g/dL, 
leukocytosis (12,900/uL), normal differential and platelet 
counts, erythrocyte sedimentation rate (ESR) 33 mm, 
aspartate transaminase (AST) 76 U/L (normal up to 32), 
alanine transaminase (ALT) 30 U/L (normal up to 31), lactic 
dehydrogenase (LDH) 550 U/L (normal up to 264), creatine 
kinase (CK) 31 U/L (26-140), aldolase 9.8 U/L (1.2-8.8), 
normal protein electrophoresis, negative antinuclear (ANA) 
and anticardiolipin antibodies, and normal complement and 
urinalysis. The myelogram and echocardiogram were also 
normal.
The chest X-ray showed a condensation on the right and 
bibasilar infiltrate. Muscular biopsy revealed perifascicular 
atrophy compatible with JDM. PFTs were not performed.
Fifteen days later, the patient was hospitalized again in 
another institution for a lung problem and, at that time, she 
was treated for three days with pulse methylprednisolone 
(30 mg/kg/day) and antibiotics, showing improvement of the 
vasculitis and lung problem. She was then treated with 1 mg/
kg/day of prednisone. In that hospitalization, laboratory tests 
showed leukocytosis and neutrophilia, increased inflammatory 
activity tests, AST 200 U/L, ALT 96 U/L, LDH 917 U/L, CK 
63 U/L, aldolase 12.5 U/L, and normal protein electrophoresis 
and urinalysis.
The echocardiogram showed ejection fraction of 0.58, 
diffuse myocardial hypokinesis, and a small pericardial 
effusion; ultrasound of the abdomen showed hepatomegaly.
Chest X-ray showed congestion, bibasilar infiltrate, and 
an increase in the size of the heart. Tomography of the chest 
revealed congested hila, severe infiltrate in the lower lobes, and 
increase in the size of the heart, but no pleural effusion.
The patient was discharged on naproxen (16 mg/kg/day) 
and prednisone (1 mg/kg/day). Three weeks later, the patient 
developed respiratory distress, tachycardia, and crackles in 
the right lung base without fever or worsening of the skin 
lesions. She also presented severe Raynaud’s phenomenon in 
the extremities. The patient was admitted to the intensive care 
unit for cardiac and respiratory failure.
She evolved with fever spikes, and acute respiratory 
failure and a reduction in oxygen saturation requiring 
orotracheal intubation. Pulse methylprednisolone (30 
mg/kg/day) was prescribed, but her respiratory function 
deteriorated progressively and the patient died three days 
after hospital admission. The chest X-ray was suggestive of 
alveolo-interstitial involvement (Figure 1). Urine and blood 
cultures were negative (including fungi), gastric washing 
was negative for alcohol-acid resistant bacilli, and serologies 
for mononucleosis, human immunodeficiency virus (HIV), 
and herpes virus were negative. Serology for IgG and IgM 
cytomegalovirus (CMV) was positive; anti-Jo 1 negative.
Lung lesions with alveolar hemorrhage, hyperplasia 
type II pneumocytes, and hyaline membrane, characterizing 
diffuse alveolar damage, were observed on autopsy. Those 
lesions, associated with infectious pneumonia, lead to acute 
respiratory distress, cardiac ischemia, circulatory collapse, 
and death (Figure 2). Indications of lung infection with CMV 
were not observed.
DISCUSSION
JDM is a systemic autoimmune vasculopathy that affects, 
mainly, the skin and muscles, with a characteristic cutaneous 
rash and proximal myopathy, which can also affect other 
organs, such as the gastrointestinal tract and lungs, which are 
associated with uncertain prognosis.1-6
The patient presented here had diagnostic criteria for 
JDM:8 symmetrical muscular weakness, cutaneous vasculitis, 
increased muscle enzymes, and muscle biopsy compatible 
with JDM.
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Figure 2. Diffuse alveolar involvement. Hyaline membrane, proteinous 
matter, inflammatory interstitial infiltrate, and pneumocyte hyperplasia 
can be seen.
There are few reports of lung involvement in children with 
JDM,1,3,4,6 which is associated with a worse prognosis and 
can manifest even before the development of cutaneous and 
musculoskeletal signs and symptoms.1,3,4
In a study by Trapani et al.1 with 12 patients with JDM, 50% of 
the patients had asymptomatic lung disease detected by PFTs.
The presentation of ILD can be acute or chronic, 
associated with coughing, dyspnea, and lung infiltrate. It 
can be asymptomatic with altered PFTs and normal imaging 
exams.2 In the study performed by Kang et al.9 diffuse alveolar 
damage and interstitial pneumonia in the lung biopsy were 
associated with a worse evolution of the ILD in adults with 
DM and polymyositis. In the patient presented here, the lung 
evaluation during autopsy showed diffuse alveolar damage 
and pneumonia, which could have contributed for the acute 
deterioration of the respiratory function.
The association of ILD with the Jo1 autoantibody, 
characterizing the antisynthetase syndrome, has been 
reported.1,2,3,5,9 This syndrome is rare in children, and it is 
characterized by non-erosive arthritis, Raynaud’s phenomenon, 
fever, and interstitial lung disease, with severe dyspnea and 
pulmonary fibrosis. It is associated with a poor prognosis, with 
a 70% survival in five years.1 The patient presented here had 
non-erosive arthritis, Raynaud’s phenomenon, and interstitial 
lung involvement. Anti-Jo1 was negative, but it can be negative 
in up to 69% of the patients with DM and ILD.3,10
Despite the positive CMV serology, postmortem tissue 
staining did not show indications of lung infection with CMV. 
The autopsy results were suggestive of infectious pneumonia, 
but the etiological agent was not identified.
The use of cyclosporine and cyclophosphamide, with 
improvement of lung function in adults and children with ILD, 
has been reported.6,11 However, although it was indicated in 
the patient in question, pulse cyclophosphamide was not used 
due to the fulminant course of her disease.
The presence of ILD in patients with JDM is associated 
with a poor prognosis. Chest X-ray and high-resolution 
tomography, pulmonary function tests, and anti-Jo1 should 
be done in patients with JDM for an early diagnosis of lung 
involvement and treatment.
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